Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
Conditions: Myasthenia Gravis Interventions: Drug: CD19-BCMA Targeted CAR-T Dose 1; Drug: CD19-BCMA Targeted CAR-T Dose 2; Drug: CD19-BCMA Targeted CAR-T Dose 2 Sponsors: Ting Chang, MD Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Myasthenia Gravis | Research